Search for content, post, videos
Advertisement

Elicera receives approval to initiate clinical Phase I/II-study

Jamal El-Mosleh
Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed. "The treatment has the potential to become a very important alternative
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.